Addex Therapeutics (ADXN) Non Operating Interest Expenses (2019 - 2026)
Addex Therapeutics (ADXN) posted Non Operating Interest Expenses of -$3393.0 for Q1 2026, down 232.21% sequentially from -$1021.3 in Q3 2025, and up 84.07% YoY from -$1843.3 in Q1 2025.
Addex Therapeutics (ADXN) Non Operating Interest Expenses (2019 - 2026) Analysis & Trends
Addex Therapeutics has reported Non Operating Interest Expenses for 8 years, with the latest figure at -$3393.0 in Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Interest Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 11.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 39.74 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 82.05 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -4.89 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 20.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 93.62 Mn |
| 10 | Addex Therapeutics | 534.71 Mn | 534.71 Mn | - | -3,393.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3,393.00 |
| Sep 30, 2025 | -1,021.34 |
| Jun 30, 2025 | 7,039.58 |
| Mar 31, 2025 | -21,299.60 |
| Sep 30, 2024 | -13,766.23 |
| Jun 30, 2024 | -955.41 |
| Mar 31, 2024 | -700.01 |
| Sep 30, 2023 | 28,127.20 |
| Jun 30, 2023 | -154,106.38 |
| Mar 31, 2023 | -28,303.76 |
| Sep 30, 2022 | 57,709.10 |
| Jun 30, 2022 | -134,191.06 |
| Mar 31, 2022 | -66,316.60 |
| Sep 30, 2021 | -10,879.31 |
| Jun 30, 2021 | -25,155.99 |
| Mar 31, 2021 | -22,939.67 |
| Sep 30, 2020 | -218,665.82 |
| Jun 30, 2020 | -157,410.12 |
| Mar 31, 2020 | -56,861.56 |
| Sep 30, 2019 | -26,081.21 |